If I had the money this would be the first person I would call.
Can one forgotten organ hold the key to reversing aging? In this exclusive interview, Dr. Greg Fahy — one of the world’s leading longevity scientists — reveals groundbreaking discoveries about the thymus, age reversal, and the future of human health.
From regrowing his own thymus to pioneering cryobiology and organ preservation, Dr. Fahy shares insights that could change how we think about aging, immortality, and life extension. This conversation dives into the science behind reversing biological age, restoring the immune system, and even the possibility of medical time travel.
🔑 Topics covered in this video:
Thymus regeneration and why it may be the “master control” of aging.
Neuroinflammation, a prolonged activation of the brain’s immune system prompted by infections or other factors, has been linked to the disruption of normal mental functions. Past studies, for instance, have found that neuroinflammation plays a central role in neurodegenerative diseases, medical conditions characterized by the progressive degradation of cells in the spinal cord and brain.
When inflammation is taking place, cells release proteins that act as signals between immune cells, also known as cytokines. While some studies have linked a specific cytokine called interleukin-1 (IL-1) to changes in brain function, the mechanisms through which it could contribute to a decline in mental capabilities remain poorly understood.
Researchers at the University of Toulouse INSERM and CNRS recently carried out a study involving mice aimed at better understanding these mechanisms. Their paper, published in Nature Neuroscience, particularly focused on neuroinflammation elicited by the parasite Toxoplasma gondii (T. gondii), which is responsible for a well-known illness called toxoplasmosis.
WARNING: AI could end humanity, and we’re completely unprepared. Dr. Roman Yampolskiy reveals how AI will take 99% of jobs, why Sam Altman is ignoring safety, and how we’re heading toward global collapse…or even World War III.
Dr. Roman Yampolskiy is a leading voice in AI safety and a Professor of Computer Science and Engineering. He coined the term “AI safety” in 2010 and has published over 100 papers on the dangers of AI. He is also the author of books such as, ‘Considerations on the AI Endgame: Ethics, Risks and Computational Frameworks’
He explains: ⬛How AI could release a deadly virus. ⬛Why these 5 jobs might be the only ones left. ⬛How superintelligence will dominate humans. ⬛Why ‘superintelligence’ could trigger a global collapse by 2027 ⬛How AI could be worse than nuclear weapons. ⬛Why we’re almost certainly living in a simulation.
00:00 Intro. 02:28 How to Stop AI From Killing Everyone. 04:35 What’s the Probability Something Goes Wrong? 04:57 How Long Have You Been Working on AI Safety? 08:15 What Is AI? 09:54 Prediction for 2027 11:38 What Jobs Will Actually Exist? 14:27 Can AI Really Take All Jobs? 18:49 What Happens When All Jobs Are Taken? 20:32 Is There a Good Argument Against AI Replacing Humans? 22:04 Prediction for 2030 23:58 What Happens by 2045? 25:37 Will We Just Find New Careers and Ways to Live? 28:51 Is Anything More Important Than AI Safety Right Now? 30:07 Can’t We Just Unplug It? 31:32 Do We Just Go With It? 37:20 What Is Most Likely to Cause Human Extinction? 39:45 No One Knows What’s Going On Inside AI 41:30 Ads. 42:32 Thoughts on OpenAI and Sam Altman. 46:24 What Will the World Look Like in 2100? 46:56 What Can Be Done About the AI Doom Narrative? 53:55 Should People Be Protesting? 56:10 Are We Living in a Simulation? 1:01:45 How Certain Are You We’re in a Simulation? 1:07:45 Can We Live Forever? 1:12:20 Bitcoin. 1:14:03 What Should I Do Differently After This Conversation? 1:15:07 Are You Religious? 1:17:11 Do These Conversations Make People Feel Good? 1:20:10 What Do Your Strongest Critics Say? 1:21:36 Closing Statements. 1:22:08 If You Had One Button, What Would You Pick? 1:23:36 Are We Moving Toward Mass Unemployment? 1:24:37 Most Important Characteristics.
NEW YORK and TRUMBULL, Conn., April 30, 2025 /PRNewswire/ — Apertura Gene Therapy, a biotechnology company focused on innovative gene therapy solutions, and the Rett Syndrome Research Trust (RSRT), an organization working to cure Rett Syndrome, today announced a collaboration to license Apertura’s human transferrin receptor 1 capsid (TfR1 CapX). This partnership aims to advance innovative genetic medicine approaches for the treatment of Rett Syndrome, a rare genetic neurological disorder caused by random mutations in the MECP2 gene on the X chromosome that primarily affect females, causing developmental regression and severe motor and language impairments.
Apertura’s TfR1 CapX is an intravenously delivered adeno-associated virus (AAV) capsid engineered to bind the transferrin receptor 1(TfR1), enabling efficient delivery of genetic medicines across the blood-brain barrier (BBB). TfR1 is a well-characterized BBB-crossing receptor, broadly and consistently expressed throughout life—even in the context of neurological disease—making it an attractive target for CNS delivery in disorders like Rett syndrome. Developed by Apertura’s academic founder, Dr. Ben Deverman, Director of Vector Engineering at the Broad Institute, TfR1 CapX has shown strong CNS selectivity in preclinical studies, achieving over 50% neuronal and 90% astrocyte transduction across multiple brain regions. Because Rett syndrome affects the brain diffusely, broader cellular transduction may correlate with greater symptomatic improvement.
Cancer specialists have long known that anemia, caused by a lack of healthy red blood cells, often arises when cancer metastasizes to the bone, but it’s been unclear why. Now, a research team led by Princeton University researchers Yibin Kang and Yujiao Han has uncovered exactly how this happens in metastatic breast cancer, and it involves a type of cellular hijacking. The research aims to help slow down bone metastasis—one of cancer’s deadliest forms.
In a study published in the journal Cell on September 3, Kang and Han reveal that cancer cells effectively commandeer a specialized cell that normally recycles iron in the bone, known as an erythroblast island (EBI) macrophage. This both deprives red blood cells of necessary iron and helps the tumor continue to grow in the bone.
Understanding metastatic cancer—or cancer that grows and spreads in other parts of the body beyond the original tumor site—is critically important. It is one of the deadliest forms of cancer and there is no cure. Of patients who die from breast and prostate cancer, 70% have bone metastasis.
Neural networks are computing systems designed to mimic both the structure and function of the human brain. Caltech researchers have been developing a neural network made out of strands of DNA instead of electronic parts that carries out computation through chemical reactions rather than digital signals.
An important property of any neural network is the ability to learn by taking in information and retaining it for future decisions. Now, researchers in the laboratory of Lulu Qian, professor of bioengineering, have created a DNA-based neural network that can learn. The work represents a first step toward demonstrating more complex learning behaviors in chemical systems.
A paper describing the research appears in the journal Nature on September 3. Kevin Cherry, Ph.D., is the study’s first author.
For all their technological brilliance, from navigating distant planets to performing complex surgery, robots still struggle with a few basic human tasks. One of the most significant challenges is dexterity, which refers to the ability to grasp, hold and manipulate objects. Until now, that is. Scientists from the Toyota Research Institute in Massachusetts have trained a robot to use its entire body to handle large objects, much like humans do.
SeeMe, a computer vision tool tested by Stony Brook University researchers, was able to detect low-amplitude, voluntary facial movements in comatose acute brain injury patients days before clinicians could identify overt responses.
Close friends know that I have a standing “do not unplug” order should I ever fall into an unresponsive state. If there is even a flicker of a chance that the mind is still working, I will be fine. Keep me plugged in and hang a “do not disturb” sign on whatever apparatus is keeping me alive.
It’s not like you can know in advance what it’s like, but it seems relaxed enough, with plenty of time to think, and I haven’t really gained anything useful from conversations with other humans in years (aside from my editors who always provide valuable information). If it is at all like sleeping, there might be dreams, so, perchance, that’s what I’d be doing in a comatose state. But for the friends by my bedside, how to be certain that the mind is still flickering?
Researchers at Beijing Genomics and IMDEA Nanociencia institutes have introduced a novel method that could significantly accelerate efficiency and reduce the cost of handling fluidics in DNA sequencing.
Traditional DNA sequencing relies on flow cells, where liquid reagents are repeatedly pumped in and out for each of the sequencing reactions. For large-scale sequencing, this process involves immersing silicon wafers into reagents—a method that works well at industrial scale but is impractical for smaller labs or clinical settings, where sample sizes are limited and drying effects become a problem.
The new approach turns that process on its head. Instead of pumping fluids through a chamber, the researchers use a roll-to-roll technique that gently shears the liquid across the surface. This dramatically improves efficiency, allowing reagents to be replaced more quickly and uses up to 85 times less material. As a result, DNA sequencing that once took days can now be completed in under 12 hours, with significantly lower reagent costs.
